Wednesday, Novartis AG NVS reported fourth-quarter 2023 net sales of $11.42 billion, up 8% (up 10% at constant currency, cc) driven by volume growth of 13 percentage points. The sales fell short of the consensus of $11.76 billion.
Generic competition had a negative impact of 3 percentage points, and pricing had no impact.
Sales growth was mainly driven by a continued strong performance from Entresto (+26% cc), Kisqali (+76% cc), Kesimpta (+73% cc), Cosentyx (+21% cc), and Pluvicto (+53% cc).
Core operating income reached $3.8 billion (+5%, +13% cc), mainly driven by higher net sales, partly offset by higher SG&A and R&D investments.
Core net income was $3.1 billion (+6%, +11% cc), mainly due to higher core operating income.
The company reported core EPS of $1.53, up from $1.32 a year ago but below the consensus of $1.62.
Dividend: The Novartis Board of Directors proposes a dividend payment of CHF 3.30 per share for 2023, up 3.1% from CHF 3.20 per share in the prior year.
Guidance: For the fiscal year 2024, Novartis expects net sales to grow mid-single digits and core operating income is expected to grow high single-digit.
Novartis also extended its mid-term guidance, expecting sales to grow 5% per year until 2028. During its R&D day, Novartis updated investors on its research and development and said its mid-term sales guidance is upgraded to 5% CAGR (2022-27) versus 4% expected earlier.
The company confirms its core operating income margin will expand to ~40%+ by 2027.
Read Next: Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition.
Price Action: NVS shares are down 3.02% at $104.50 during the premarket session on the last check Wednesday.
Photo via Wikimedia Commons
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
